Sijben Hubert J, Dall' Acqua Laura, Liu Rongfang, Jarret Abigail, Christodoulaki Eirini, Onstein Svenja, Wolf Gernot, Verburgt Simone J, Le Dévédec Sylvia E, Wiedmer Tabea, Superti-Furga Giulio, IJzerman Adriaan P, Heitman Laura H
Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Medical University of Vienna, Vienna, Austria.
Front Pharmacol. 2022 May 23;13:872335. doi: 10.3389/fphar.2022.872335. eCollection 2022.
Excitatory amino acid transporters (EAAT/SLC1) mediate Na-dependent uptake of extracellular glutamate and are potential drug targets for neurological disorders. Conventional methods to assess glutamate transport are based on radiolabels, fluorescent dyes or electrophysiology, which potentially compromise the cell's physiology and are generally less suited for primary drug screens. Here, we describe a novel label-free method to assess human EAAT function in living cells, i.e., without the use of chemical modifications to the substrate or cellular environment. In adherent HEK293 cells overexpressing EAAT1, stimulation with glutamate or aspartate induced cell spreading, which was detected in real-time using an impedance-based biosensor. This change in cell morphology was prevented in the presence of the Na/K-ATPase inhibitor ouabain and EAAT inhibitors, which suggests the substrate-induced response was ion-dependent and transporter-specific. A mechanistic explanation for the phenotypic response was substantiated by actin cytoskeleton remodeling and changes in the intracellular levels of the osmolyte taurine, which suggests that the response involves cell swelling. In addition, substrate-induced cellular responses were observed for cells expressing other EAAT subtypes, as well as in a breast cancer cell line (MDA-MB-468) with endogenous EAAT1 expression. These findings allowed the development of a label-free high-throughput screening assay, which could be beneficial in early drug discovery for EAATs and holds potential for the study of other transport proteins that modulate cell shape.
兴奋性氨基酸转运体(EAAT/SLC1)介导细胞外谷氨酸钠依赖性摄取,是神经系统疾病的潜在药物靶点。评估谷氨酸转运的传统方法基于放射性标记、荧光染料或电生理学,这些方法可能会损害细胞的生理功能,并且通常不太适合初级药物筛选。在这里,我们描述了一种在活细胞中评估人类EAAT功能的新型无标记方法,即不使用对底物或细胞环境进行化学修饰的方法。在过表达EAAT1的贴壁HEK293细胞中,用谷氨酸或天冬氨酸刺激会诱导细胞铺展,使用基于阻抗的生物传感器可实时检测到这种现象。在存在钠钾ATP酶抑制剂哇巴因和EAAT抑制剂的情况下,这种细胞形态变化受到抑制,这表明底物诱导的反应是离子依赖性和转运体特异性的。肌动蛋白细胞骨架重塑和渗透剂牛磺酸细胞内水平的变化证实了表型反应的机制解释,这表明该反应涉及细胞肿胀。此外,在表达其他EAAT亚型的细胞以及内源性表达EAAT1的乳腺癌细胞系(MDA-MB-468)中也观察到底物诱导的细胞反应。这些发现促成了一种无标记高通量筛选测定法的开发,这可能有助于EAATs的早期药物发现,并为研究其他调节细胞形状的转运蛋白具有潜在价值。